Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Tacrolimus compared with cyclosporine A after haploidentical T-cell replete transplantation with post-infusion cyclophosphamide

Bone Marrow Transplantation volume 51, pages 462–465 (2016)Cite this article

Subjects

An Erratum to this article was published on 02 March 2016

Different strategies have been developed to perform haploidentical stem cell transplantation (haplo HSCT) without graft manipulation.1, 2, 3 Investigators from the Johns Hopkins University pioneered the use of post-transplantation cyclophosphamide (PT-Cy) after a T-cell replete haploidentical bone marrow infusion. In the Baltimore scheme tacrolimus (FK), with mycophenolate mofetil (MMF), was used to prevent GvHD and a host vs host (HVG) reaction.4 FK is a calcineurin inhibitor that is almost 100-fold more potent than cyclosporine A (CyA) in its inhibitory activity and more active in clinical trials.5, 6, 7

In this retrospective study, we analyzed 100 patients grafted with haplo HSCT with PT-Cy and receiving FK or CyA.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Lee KH, Lee JH, Lee JH, Kim DY, Kim SH, Shin HJ et al. Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin. Biol Blood Marrow Transplant 2009; 15: 61–72.

    Article  CAS  PubMed  Google Scholar 

  2. Huang XJ, Zhu HH, Chang YJ, Xu LP, Liu DH, Zhang XH et al. The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate- or high-risk acute myeloid leukemia in first complete remission. Blood 2012; 119: 5584–5590.

    Article  CAS  PubMed  Google Scholar 

  3. Di Bartolomeo P, Santarone S, De Angelis G, Picardi A, Cudillo L, Cerretti R et al. Haploidentical, unmanipulated, G-CSF-primed bone marrow transplantation for patients with high-risk hematologic malignancies. Blood 2013; 121: 849–857.

    Article  CAS  PubMed  Google Scholar 

  4. Luznik L, O'Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008; 14: 641–650.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Jacobson P, Uberti J, Davis W, Ratanatharathorn V . Tacrolimus: a new agent for the prevention of graft-versus-host disease in hematopoietic stem cell transplantation. Bone Marrow Transplant 1998; 22: 217–225.

    Article  CAS  PubMed  Google Scholar 

  6. Ratanatharathorn V, Nash RA, Przepiorka D, Devine SM, Klein JL, Weisdorf D et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998; 92: 2303–2314.

    CAS  PubMed  Google Scholar 

  7. Nash RA, Antin JH, Karanes C, Fay JW, Avalos BR, Yeager AM et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000; 96: 2062–2068.

    CAS  PubMed  Google Scholar 

  8. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912–2919.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825–828.

    CAS  PubMed  Google Scholar 

  10. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945–956.

    Article  PubMed  Google Scholar 

  11. Yanada M, Emi N, Naoe T, Sakamaki H, Takahashi S, Hirabayashi N et al. Tacrolimus instead of cyclosporine used for prophylaxis against graft-versus-host disease improves outcome after hematopoietic stem cell transplantation from unrelated donors, but not from HLA-identical sibling donors: a nationwide survey conducted in Japan. Bone Marrow Transplant 2004; 34: 331–337.

    Article  CAS  PubMed  Google Scholar 

  12. Jagasia M, Arora M, Flowers ME, Chao NJ, McCarthy PL, Cutler CS et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood 2012; 119: 296–307.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Devillier R, Crocchiolo R, Castagna L, Fürst S, El Cheikh J, Faucher C et al. The increase from 2.5 to 5 mg/kg of rabbit anti-thymocyte-globulin dose in reduced intensity conditioning reduces acute and chronic GVHD for patients with myeloid malignancies undergoing allo-SCT. Bone Marrow Transplant 2012; 47: 639–645.

    Article  CAS  PubMed  Google Scholar 

  14. Holtan SG, DeFor TE, Lazaryan A, Bejanyan N, Arora M, Brunstein CG et al. Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation. Blood 2015; 125: 1333–1338.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, Humanitas Cancer Center, Istituto Clinico Humanitas, Rozzano, Italy

    L Castagna, S Bramanti, B Sarina, R Crocchiolo, L Morabito, C Carlo-Stella & A Santoro

  2. Department of Hematology, Transplantation Program Institut Paoli Calmettes, Marseille, France

    S Furst, J El Cheikh, A Granata, C Faucher, B Mohty, S Harbi, R Devillier & D Blaise

  3. Statistic Unit, Humanitas Cancer Center, Istituto Clinico Humanitas, Rozzano, Italy

    L Giordano

  4. Department of Hematology, Ospedale Ferrarotto, Catania, Italy

    E Mauro

  5. Cell Therapy Unit Institut Paoli Calmettes, Marseille, France

    C Chabannon

  6. Aix-Marseille Université, Marseille, France

    C Chabannon & D Blaise

  7. Centre de Recherche en Cancérologie de Marseille (CRCM), Marseille, France

    C Chabannon & D Blaise

Authors
  1. L Castagna
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Bramanti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S Furst
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L Giordano
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. B Sarina
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R Crocchiolo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J El Cheikh
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A Granata
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. L Morabito
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. E Mauro
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. C Faucher
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. B Mohty
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. S Harbi
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. R Devillier
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. C Chabannon
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. C Carlo-Stella
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. A Santoro
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. D Blaise
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L Castagna.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Castagna, L., Bramanti, S., Furst, S. et al. Tacrolimus compared with cyclosporine A after haploidentical T-cell replete transplantation with post-infusion cyclophosphamide. Bone Marrow Transplant 51, 462–465 (2016). https://doi.org/10.1038/bmt.2015.289

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2015.289

This article is cited by

Search

Advanced search

Quick links